FindTrial
Sign In

Analysing the Graft versus host disease in allogenic stem cell transplant patient by adding with or without sitagliptin.

Open labelled, randomized controlled trial of All allogenic hematopoietic stem cell transplantation (HSCT) with standard graft versus host disease (GVHD) prophylaxis with or without sitagliptin.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/12/038469
Enrollment
398
Registered
2021-12-07
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D758- Other specified diseases of bloodand blood-forming organs

Interventions

Intervention1: Sitagliptin: tablet sitagliptin 600mg twice a day per oral for 14 days Control Intervention1: Standard GVHD prophylaxis with out sitagliptin: 1 cyclophosphamide 50mg per kg once a day f

Sponsors

Dr Sachin Suresh Jadhav
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: all patients undergoing an allogeneic HSCT in our Department

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Incidence of acute GVHD as per National Institutes of Health (NIH) consensus criteriaTimepoint: 5 years—

Secondary

MeasureTime frame
Chronic GVHD at last follow-up Relapse free survival at last follow-up Overall survival at last follow-up Timepoint: 5 years—

Countries

India

Contacts

Public ContactDr Sachin Suresh Jadhav

HCG Cancer Hospital, bangalore

drsachinjadhav@hotmail.com9741351357

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026